<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975037</url>
  </required_header>
  <id_info>
    <org_study_id>CYP3A_DDI</org_study_id>
    <nct_id>NCT02975037</nct_id>
  </id_info>
  <brief_title>Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors</brief_title>
  <official_title>Evaluation and Validation of Metabolic Markers for the Prediction of Drug-drug Interaction of Various CYP3A4 Substrates and Inhibitors in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation and validation of metabolic markers for the prediction of drug-drug interaction of
      various CYP3A4 substrates (sildenafil) and inhibitors (erythromycin/itraconazole) in healthy
      male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects suitable for this study will be admitted to the Clinical Trials Center, Seoul
      National University Hospital on the day before dosing, and they will be overnight-fasted from
      9P of Day -1. Urine collection is scheduled from 12 hours before sildenafil administration to
      12 hours after administration. Subjects will be administered sildenafil (oral) around at 9A
      of Day 1. Subjects will perform scheduled procedures including clinical laboratory tests,
      electrocardiograms and blood samplings for pharmacokinetic, pharmacometabolomic and mRNA
      assessment.

      Subjects will be administered either erythromycin or itraconazole (oral) around at 9A on Day
      3 and 9A/9P on Day 4. Urine collection is scheduled from 0 hour to 12 hours after Day 3
      erythromycin or itraconazole administration. Subjects will perform scheduled procedures
      including clinical laboratory tests, electrocardiograms and blood samplings for
      pharmacokinetic, pharmacometabolomic and mRNA assessment.

      On Day 5, sildenafil will be administered with erythromycin or itraconazole around at 9A.
      Urine collection is scheduled from 12 hours before Day 5 drug administration to 12 hours
      after administration. Subjects will perform scheduled procedures. After subjects perform
      scheduled procedure, the study will be discharged (around 9A of Day 6).

      Study participation was terminated on post-study visit (Day 12-14).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of endogenous metabolites (plasma)</measure>
    <time_frame>day 1 0h, day 3 0h, day 5 0h</time_frame>
    <description>Metabolomic profiles to predict CYP3A activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of endogenous metabolites (urine)</measure>
    <time_frame>day -1 12h~day 1 0h, day 1 0h~12h, day 3 0h~12h, day 4 12h~ day 5 0h, day 5 0h~12h</time_frame>
    <description>Metabolomic profiles to predict CYP3A activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>day 1 0h (pre-dose), 10, 20, 30, 45 min, 1, 2, 3, 4, 6, 8, 12, 24h; day 3 0h (pre-dose), 10, 20, 30, 45 min, 1, 2, 3, 4, 6, 8, 12, 24h; day 5 0h (pre-dose), 10, 20, 30, 45 min, 1, 2, 3, 4, 6, 8, 12, 24h</time_frame>
    <description>Pharmacokinetics of CYP3A substrate and inhibitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>day 1 0h (pre-dose), 10, 20, 30, 45 min, 1, 2, 3, 4, 6, 8, 12, 24h; day 3 0h (pre-dose), 10, 20, 30, 45 min, 1, 2, 3, 4, 6, 8, 12, 24h; day 5 0h (pre-dose), 10, 20, 30, 45 min, 1, 2, 3, 4, 6, 8, 12, 24h</time_frame>
    <description>Pharmacokinetics of CYP3A substrate and inhibitors</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quantification of mRNA (whole blood)</measure>
    <time_frame>day -1 12h, day 1 0, 12h, day 3 0, 12h, day 4 12h, day 5 0, 12h</time_frame>
    <description>Quantification of mRNA for CYP3A activity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>sildenafil+erythromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil 25 mg PO (single dose); Erythromycin 250 mg PO (3 doses); Sildenafil 25 mg PO + Erythromycin 250 mg PO (single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sildenafil+itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil 25 mg PO (single dose); Itraconazole 100 mg PO (3 doses); Sildenafil 25 mg PO + Itraconazole 100 mg PO (single dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>sildenafil 25 mg PO</description>
    <arm_group_label>sildenafil+erythromycin</arm_group_label>
    <arm_group_label>sildenafil+itraconazole</arm_group_label>
    <other_name>VIAGRA TAB, Pfizer Pharmaceuticals Korea Limited, Korea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <description>erythromycin 250 mg PO</description>
    <arm_group_label>sildenafil+erythromycin</arm_group_label>
    <other_name>ERYTHIN CAP 250MG, Wooridul Pharmaceutical Co.,Ltd., Korea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>itraconazole 100 mg PO</description>
    <arm_group_label>sildenafil+itraconazole</arm_group_label>
    <other_name>ITRA TAB, Hanmi Pharm.Co.,Ltd., Korea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: Between 19 to 50 years of age, inclusive

          -  Weight: within 17-28 of Body Mass Index (BMI)

          -  Subject who are reliable and willing to make themselves available during the study
             period.

          -  Subject who are willing to follow the study protocol, and give their written informed
             consent voluntarily.

        Exclusion Criteria:

          -  History of hypersensitive reaction to medication (midazolam, itraconazole, rifampicin)

          -  History of significant clinical illness needs medical caution, including
             cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory,
             gastrointestinal, hepatic, or renal disease or other chronic disease

          -  History or evidence of drug abuse

          -  Use any prescriptive medication, Korean traditional medication not considered
             acceptable by the clinical investigator during the last 14 days period before first
             dosing, or use any medication not considered acceptable by the clinical investigator
             during the last 7 days period before first dosing (if used medication is considered
             acceptable by investigator, patients can be included)

          -  Participation in clinical trials of any drug within 3 months prior to the
             participation of the study

          -  Judged to be inappropriate for the study by the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Joo-Youn Cho</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

